This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BIOS BioPlus Acquisition (BIOS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About BioPlus Acquisition Stock (NASDAQ:BIOS) 30 days 90 days 365 days Advanced Chart Get BioPlus Acquisition alerts:Sign Up Key Stats Today's Range$10.79▼$10.8050-Day Range$10.75▼$10.8452-Week Range$10.05▼$11.68Volume5,636 shsAverage Volume122,781 shsMarket Capitalization$209.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioPlus Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. BioPlus Acquisition Corp. was incorporated in 2021 and is based in New York, New York. Read More Receive BIOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioPlus Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOS Stock News HeadlinesUpstream Bio Pursues $100 Million IPO Plan With Encouraging Trial ResultsSeptember 25, 2024 | seekingalpha.comPayMate Plans to Acquire DigiAsia BiosSeptember 24, 2024 | marketwatch.comThis Crypto Is Set to Explode in JanuaryFree summit reveals where Bitcoin goes after $120k Don't miss this rare opportunity to learn directly from the experts who are driving this market…August 2 at 2:00 AM | Crypto 101 Media (Ad)Gigabyte details BIOS roll-out plan to neutralize Sinkclose vulnerability — eligible AMD CPUs should be patched by end of the monthAugust 24, 2024 | yahoo.comMadison's Mirus Bio to be acquired by MilliporeSigma for $600 millionMay 28, 2024 | bizjournals.comBiogen enters deal to acquire HI-Bio for $1.8bnMay 23, 2024 | msn.comBiogen’s Strategic Acquisition of HI-Bio and Diversification into Orphan Drug Market Prompt ‘Buy’ RatingMay 22, 2024 | markets.businessinsider.comBiogen to buy San Francisco startup developing a drug for kidney disease for $1.2BMay 22, 2024 | bizjournals.comSee More Headlines BIOS Stock Analysis - Frequently Asked Questions When did BioPlus Acquisition IPO? BioPlus Acquisition (BIOS) raised $180 million in an initial public offering (IPO) on Friday, December 3rd 2021. The company issued 18,000,000 shares at $10.00 per share. Cantor served as the underwriter for the IPO. What other stocks do shareholders of BioPlus Acquisition own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioPlus Acquisition investors own include TransMedics Group (TMDX), Deciphera Pharmaceuticals (DCPH) and BioMarin Pharmaceutical (BMRN). Company Calendar Today8/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:BIOS CIK1856653 Webbioplusspac.com Phone212-287-4092FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares19,370,000Free Float14,990,000Market Cap$209.10 million OptionableNot Optionable Beta0.01 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:BIOS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPlus Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPlus Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
